History

The Story So Far

Onyx Biotec is a 21-year-old private pharmaceutical contract manufacturer that has only been a public company for 18 months. The narrative arc is short and asymmetric: a long single-product chapter (Sterile Water for Injections, 2010–2023), a recent diversification into cephalosporin dry-powder injectables and syrups (Unit II commissioned March 2023), an oversubscribed SME-Emerge IPO (November 2024), one strong fiscal year as a listed company (FY2025), and an immediate slip into loss in FY2026. Management credibility is therefore measured against a thin track record — and the first real test, the post-IPO promise of "better operational and financial performance in FY2026," has been missed.

1. The Narrative Arc

The chronology has three real chapters. Chapter 1 (2005–2022) was a single-product sterile-water franchise built around long-term contracts with India's top pharma names — Mankind, Sun Pharma, Dr Reddy's, Aristo, Macleods. Revenue oscillated (₹44.9 Cr in FY2022, dropping to ₹39.5 Cr in FY2023) but the business was profitable. Chapter 2 (March 2023 onwards) is the diversification chapter: Unit II added two new product lines (dry-powder injections and dry syrups, both cephalosporins) and dragged FY2024 revenue up 36% to ₹53.7 Cr — even though Unit II was only operational for one month of FY2023. Chapter 3 (November 2024 onwards) is the public-company chapter, which is what investors are actually pricing.

The OPM chart is the single most important picture in the file. After three years of margin expansion (11.4% → 15.6% → 16.8%), FY2026 OPM collapsed to 4.9% — wiping out PAT and ending the year in a small loss despite revenue growing 12%. This is a cost or pricing shock, not a demand shock.

2. What Management Emphasized — and Then Stopped Emphasizing

Three patterns stand out:

• Risk language nearly disappeared after the IPO. The DRHP enumerated 26 detailed business risks across customer concentration, geographic concentration, raw material supplier concentration, and capex delays. The FY2025 Annual Report compressed this entire section to a single paragraph titled "Risk Management Policy" with no quantified disclosure. This is partly structural — SME-Emerge listings are exempt from many SEBI disclosure regs — but it is also a narrative choice.
• "Exceptional performance" framing entered with the first public-company AR and exited immediately. The Director's Report for FY2025 used the phrase "exceptional operational and financial performance" and stated the company was "well positioned to achieve better operation and financial performance in FY2026." Twelve months later FY2026 delivered a PAT loss.
• The IPO capex story (Unit I large-volume parenteral upgrade and Unit II cartooning line) has been consistently emphasized but never reported as completed. It was a five-line headline in the DRHP. It is still being tracked as "advance paid, bills will be received once machinery is delivered and installed" in the May 2026 deviation report — 18 months after listing.

3. Risk Evolution

The risk discussion got dramatically shorter once the company was listed. None of the underlying exposures changed materially — Solan concentration is still 100%, supplier concentration is still 59%+, and there are still no long-term binding customer contracts. What changed is the obligation to talk about them. The one risk that did materialise — margin compression — is the one risk that was never enumerated in any document. The FY2026 audited results carry no MD&A explanation for why operating margin collapsed by ~1,200 basis points; the audit committee minutes simply note the results were approved with an "unmodified opinion."

4. How They Handled Bad News

There is one episode worth examining: the gap between the FY2025 self-assessment and the FY2026 outcome.

There is no honest reckoning here — only silence. Management did not pre-announce, did not explain, and did not contextualise. For a public company in its second year, this is a meaningful credibility data point. The contrast between the "exceptional / well-positioned" language of May 2025 and the unannotated loss of May 2026 is the central question a reader has to weigh.

5. Guidance Track Record

The promises that actually mattered to valuation came in three buckets: (1) revenue guidance in the DRHP, (2) IPO-objects capex commitments, and (3) the FY2025 Director's-Report forward statement.

Credibility score: 5/10. The track record is genuinely mixed. Revenue guidance was beaten. The Unit II commissioning and WHO-GMP certification were delivered on a tight schedule. IPO-objects compliance is technically clean — auditors have certified "no deviation," and the loan-prepayment and GCP tranches are fully utilised. But the two growth-capex tranches (Unit I LVP upgrade, Unit II cartooning line) — the parts of the IPO story that explained why ONYX deserved a premium multiple — remain only ~72% deployed eighteen months on, and neither facility is yet producing revenue. And the single most important forward-looking statement management made — that FY2026 would be "better" — was contradicted not by a small miss but by a swing from ₹4.95 Cr profit to a loss, with no explanation provided.

The score sits at the midpoint because the team has not done anything dishonest or evasive in a regulatory sense — the disclosures exist, the auditors are clean, and the IPO money is sitting in deposits and identifiable projects — but they have demonstrated weak forecasting discipline and an unwillingness to narrate setbacks.

6. What the Story Is Now

The story Onyx Biotec is currently telling investors — implicitly, through the structure of its filings rather than through any active investor communication — is: we are a small but established sterile-injectables contract manufacturer with two operational units, a recognized customer roster, an undeployed Unit I upgrade in progress, and a recent margin issue we have not chosen to explain.

What has been de-risked since the IPO:

• Unit II is real and certified. WHO-GMP came through. The DPI/syrup product lines exist, contribute meaningful revenue (52%+ of revenue mix in May 2024 trailing data), and have customer audits behind them.
• The promoter group has not sold. Sanjay Jain and Naresh Kumar continue to hold the founding stake (promoter holding fell from 88.6% to 65.1% only because of the IPO dilution — no secondary sale by promoters).
• ₹12 Cr of debt was repaid from IPO proceeds, reducing the interest burden from ₹2.16 Cr in FY24 to ₹1.21 Cr in FY26.

What still looks stretched:

• The LVP / "move up the value chain" thesis — the highest-margin part of the post-IPO plan — has not been built yet and cannot be modelled with any confidence given the eighteen-month slippage.
• The FY2026 margin collapse is unexplained. Until management addresses it, every forward number is speculative.
• The growth story rests on India alone. Exports were ₹0.01 Cr in FY2024 — a rounding error against the "Indian and global markets" framing in every document.
• Disclosure discipline is poor by listed-market standards. SME-Emerge regulations permit minimal disclosure, and the company has used that permission fully. A reader of the FY2025 AR and FY2026 results filing alone cannot tell what changed.

What the reader should believe versus discount:

• Believe: the customer relationships, the WHO-GMP certifications, the legal/audit cleanliness, the founding-promoter alignment.
• Discount: the "exceptional performance" framing, the FY2026 timeline for the LVP business, and any management-supplied growth narrative until a public communication explains the FY2026 result.

This is a company with real assets, real customers, real cash flow until FY2026, and a credibility account that the very next half-yearly result either rebuilds or empties. There is no acquisition history, no CEO scandal, no SEC investigation, no stock-crash crisis to dissect — just a young public-company story that hit a margin wall in year two and is, as of this writing, declining to talk about it.